mit Zealand Pharma A/S gegen Diabetes



Beitrag schreiben

Begriffe und/oder Benutzer

 

Irgendwie zeigt w:o die Quartalszahlung der Zealand-Pharma nicht als Meldung an.

Ich stelle daher die Mitteilung der Gesellschaft zum Geschäftsverlauf vom 07.02.2018 mal hier rein:

Zealand reports royalty revenue for the fourth quarter of 2017


Zealand reports royalty revenue of DKK 11.3 million/USD 1.8 million for Q4 2017

The revenue is based on total net sales of Lyxumia®/Adlyxin® and Soliqua® 100/33/ Suliqua® of DKK 112.8 million/USD 18.2 million in Q4 2017

In the fourth quarter Soliqua® 100/33 sales grew 30% over the previous quarter

Copenhagen, February 7, 2018 – Zealand Pharma (“Zealand”) reports Q4 2017 royalty revenue from Sanofi’s sales of Soliqua® 100/33/ Suliqua® of DKK 7.0 million/USD 1.1 million – an increase of 30% versus previous quarter and from sales of Lyxumia®/Adlyxin® (lixisenatide) of DKK 4.3 million/USD 0.7 million. Total royalty revenue for 2017 amounted to DKK 38.8 million/USD 6.3 million an increase of 59% over previous year.

Soliqua® 100/33 is a fixed-dose combination of lixisenatide and insulin glargine 100 units/ml (Lantus®) which was launched under the brand name Soliqua® 100/33 in the United States in January 2017 and was also launched as Suliqua® in some European countries, in 2017.

Soliqua® 100/33/ Suliqua® is commercialized by Sanofi. Zealand receives 10% of global net sales and potentially up to USD 100 million in commercial milestones.

Zealand’s full-year results for 2017 will be published on March 7, 2018.


Beitrag zu dieser Diskussion schreiben